Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 2/20 | 0.35 |
| ▸ | PRKDC | P78527 | 2/20 | 0.32 |
| ▸ | ATR | Q13535 | 2/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.30 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20909030 | 0.81 | ALDH1A1 (0.41) | — | |
| SCHEMBL25810411 | 0.74 | IKBKB (0.48) | PRKDCATRATM | |
| SCHEMBL20899010 | 0.72 | PTPN11 (0.39) | PTPN11PDCD1CD274 | |
| SCHEMBL24986582 | 0.72 | KMO (0.39) | PTPN11ATM | |
| SCHEMBL30185163 | 0.72 | KMO (0.39) | PTPN11ATM | |
| SCHEMBL30185222 | 0.70 | ALPL (0.40) | PTPN11ATRCD274 | |
| SCHEMBL22366797 | 0.70 | ALPL (0.40) | PTPN11ATRCD274 | |
| Propionic Acid SCHEMBL20899011 | 0.69 | CCR4 (0.33) | PTPN11PDCD1CD274 | |
| SCHEMBL22789698 | 0.68 | PRKDC (0.45) | PTPN11PRKDCATRPDCD1CD274 | |
| SCHEMBL3701660 | 0.67 | PDE3B (0.38) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067636-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-11702411-B2 | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067636-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN1 | PTPN11 6/4885PRKDC 595/4885ATR 643/4885 |
| US-11702411-B2 | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN1 | PTPN11 6/4885PRKDC 595/4885ATR 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.